Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 219

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Interpretation of cytogenetic results in multiple myeloma for clinical practice

Open access
Rajan, A M, Rajkumar, S V · 2015 · Blood Cancer Journal

Abstract

The interpretation of cytogenetic abnormalities in multiple myeloma (MM) is often a challenging task. MM is characterized by several cytogenetic abnormalities that occur at various time points in the disease course. The interpretation of cytogenetic results in MM is complicated by the number and complexity of the abnormalities, the methods used to detect them and the disease stage at which they are detected. Specific cytogenetic abnormalities affect clinical presentation, progression of smoldering multiple myeloma (SMM) to MM, prognosis of MM and management strategies. The goal of this paper is to provide a review of how MM is classified into specific subtypes based on primary cytogenetic abnormalities and to provide a concise overview of how to interpret cytogenetic abnormalities based on the disease stage to aid clinical practice and patient management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bcj.2015.92

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 46

  1. Palumbo A, Anderson K . Multiple myeloma. N Engl J Med 2011; 364: 1046–1060. · DOI · Paper page
  2. Rajkumar SV . Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89: 998–1009. · DOI · Paper page
  3. Fonseca R . Many and multiple myeloma(s). Leukemia 2003; 17: 1943–1944. · DOI
  4. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546–1558. · DOI · Paper page
  5. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM . Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996; 93: 13931–13936. · DOI · Paper page
  6. Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp MJ, Harousseau JL et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 1999; 59: 4546–4550.
  7. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF . Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013; 121: 884–892. · DOI · Paper page
  8. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119: 2100–2105. · DOI · Paper page
  9. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210–2221. · DOI · Paper page
  10. Rajkumar SV . Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 225–235. · DOI · Paper page
  11. Rajkumar SV . Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479–491. · DOI · Paper page
  12. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R et al. Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clinic Proc 2009; 84: 1095–1110. · DOI · Paper page
  13. Kuehl WM, Bergsagel PL . Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175–187. · DOI · Paper page
  14. Bergsagel PL, Kuehl WM . Chromosome translocations in multiple myeloma. Oncogene 2001; 20: 5611–5622. · DOI · Paper page
  15. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250–4256. · DOI · Paper page
  16. Avet-Louseau H, Daviet A, Sauner S, Bataille R . Intergroupe Francophone du M. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 2000; 111: 1116–1117. · DOI
  17. Shaughnessy J Jr., Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003; 120: 44–52. · DOI
  18. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA et al. Biological and prognostic significance of interphase fluorescence is situ hybridization detection of chromosome 13 abnormalities in multiple myeloma: an Eastern Cooperative Oncology Group Study. Cancer Res 2002; 62: 715–720.
  19. Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012; 26: 349–355. · DOI · Paper page
  20. Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010; 95: 1150–1157. · DOI · Paper page
  21. Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM et al. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood 2015; 125: 831–840. · DOI
  22. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108: 1724–1732. · DOI · Paper page
  23. Sawyer JR, Tian E, Heuck CJ, Johann DJ, Epstein J, Swanson CM et al. Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. Blood 2015; 125: 3756–3759. · DOI
  24. Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE et al. Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma 2015; 56: 602–607. · DOI
  25. Kastritis E, Dimopoulos MA . Appraising myc involvement in high risk myeloma. Leuk Lymphoma 2015; 56: 551–552. · doi:10.3109/10428194.2014.961015
  26. Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res 2011; 17: 7776–7784. · DOI · Paper page
  27. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N et al. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 2007; 13: 1066–1072. · DOI
  28. Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK . Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 2014; 28: 398–403. · DOI
  29. Avet-Loiseau H, Magrangeas F, Moreau P, Attal M, Facon T, Anderson K et al. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol 2011; 29: 1893–1897. · DOI
  30. Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010; 24: 623–628. · DOI
  31. Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M et al. Relationship between elevated immunoglobulin free light chain and the presence of igh translocations in multiple myeloma. Leukemia 2010; 24: 1498–1505. · DOI
  32. Rajkumar SV, Landgren O, Mateos MV . Smoldering multiple myeloma. Blood 2015; 125: 3069–3075. · DOI · Paper page
  33. Rajkumar SV, Kyle RA . Haematological cancer: treatment of smoldering multiple myeloma. Nat Rev Clin Oncol 2013; 10: 554–555. · DOI
  34. Mateos M, Lopez-Corral L, Hernandez M, Giraldo P, De la Rubia J, De Arriba F et al. Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: a phase III, randomized, multicenter trial based on lenalidomide-dexamethasone (Len-Dex) as induction therapy followed by maintenance therapy with len alone vs no treatment. Blood 2011; 118: 3996. · DOI
  35. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR et al. Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc 2013; 88: 360–376. · DOI · Paper page
  36. Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 2012; 30: 1949–1952. · DOI · Paper page
  37. Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 2014; 28: 675–679. · doi:10.1038/leu.2013.225
  38. Pandey S, Rajkumar SV, Kapoor P, Ketterling RP, Lacy MQ, Gertz MA et al. Impact of FISH Abnormalities on Response to Lenalidomide in Patients with Multiple Myeloma. ASH Annu Meeting Abstr 2013; 122: 3210.
  39. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176–185. · DOI · Paper page
  40. Nair B, van Rhee F, Shaughnessy JD Jr., Anaissie E, Szymonifka J, Hoering A et al. Superior results of total therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010; 115: 4168–4173. · DOI · Paper page
  41. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075–2085. · DOI · Paper page
  42. Goldschmidt H, Neben K, Bertsch U, Hielscher T, van der Holt B, Hose D et al. Bortezomib-based induction therapy followed by autologous stem cell transplantation and maintenance therapy with bortezomib improves outcome in myeloma patients with gain 1q21 and t(4;14) - a subgroup analysis of the HOVON-65/GMMG-HD4 Trial. ASH Annu Meeting Abstr 2010; 116: 305.
  43. Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17 p. Blood 2012; 119: 940–948. · DOI · Paper page
  44. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clinic Proc 2004; 79: 867–874. · DOI · Paper page
  45. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia 2012; 26: 149–157. · DOI · Paper page
  46. Nemec P, Zemanova Z, Kuglik P, Michalova K, Tajtlova J, Kaisarova P et al. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma 2012; 53: 920–927. · doi:10.3109/10428194.2011.634042

Cited by

Metadata

Authors
Rajan, A. M., & Rajkumar, S. V.
Venue
Blood Cancer Journal
Published
2015-10-30
Volume
5
Issue
10
Pages
e365-e365
ISSN
2044-5385 (ISSN-L)
OpenAlex
W1912299294
Cited by
219
References
6
FWCI
12.44
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.